Loading…

Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography

Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this...

Full description

Saved in:
Bibliographic Details
Published in:Cardiorenal medicine 2015-06, Vol.5 (3), p.199-207
Main Authors: Yılmaz, Mustafa, Aydınalp, Alp, Okyay, Kaan, Tekin, Abdullah, Bal, Uğur Abbas, Bayraktar, Nilüfer, Yıldırır, Aylin, Müderrisoğlu, Haldun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063
cites cdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063
container_end_page 207
container_issue 3
container_start_page 199
container_title Cardiorenal medicine
container_volume 5
creator Yılmaz, Mustafa
Aydınalp, Alp
Okyay, Kaan
Tekin, Abdullah
Bal, Uğur Abbas
Bayraktar, Nilüfer
Yıldırır, Aylin
Müderrisoğlu, Haldun
description Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.
doi_str_mv 10.1159/000381964
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000381964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3741611051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</originalsourceid><addsrcrecordid>eNptkc1r3DAQxUVoSUKaQ-4hCHJpD24lWZLlSyCYfgSStpT2LGRZ9jr1Ss7IXtj_vjK73bSlp5lhfrx5w0PogpK3lIryHSEkV7SU_AidUil5JgRhL_Z9rpg6QecxPiaMCElLIo7RCUuNKAt2inwV1qOBPgaPQ4srAxvX9EMYsPENfnBTGCEsYxsAfwW3cX7qfYer4CcwccrufDNb1-DPblxBGM202mLTTg4SAsEb2OJb3_WhAzOutq_Qy9YM0Z3v6xn68eH99-pTdv_l4111e59ZLtiUMSOplTVnnElmbUmlZVJK09bGGpvXXFlSt8vXTpiCKm6buuCqILlUwhKZn6Gbne4412vXWLe4HfQI_To50sH0-u-N71e6CxvNeaFyRpPA670AhKfZxUmv-2jdMBjvwhw1laUiea54kdDrf9DHMINP7y2UKEpZKJGoNzvKQogRXHswQ4legtSHIBN79af7A_k7tueTPw10Dg5A9e1hJ6HHpk3U5X-p_ZVfPFSu3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695796785</pqid></control><display><type>article</type><title>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</title><source>Open Access: PubMed Central</source><creator>Yılmaz, Mustafa ; Aydınalp, Alp ; Okyay, Kaan ; Tekin, Abdullah ; Bal, Uğur Abbas ; Bayraktar, Nilüfer ; Yıldırır, Aylin ; Müderrisoğlu, Haldun</creator><creatorcontrib>Yılmaz, Mustafa ; Aydınalp, Alp ; Okyay, Kaan ; Tekin, Abdullah ; Bal, Uğur Abbas ; Bayraktar, Nilüfer ; Yıldırır, Aylin ; Müderrisoğlu, Haldun</creatorcontrib><description>Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p &lt; 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.</description><identifier>ISSN: 1664-3828</identifier><identifier>EISSN: 1664-5502</identifier><identifier>DOI: 10.1159/000381964</identifier><identifier>PMID: 26195972</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Original Paper</subject><ispartof>Cardiorenal medicine, 2015-06, Vol.5 (3), p.199-207</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>Copyright (c) 2015 S. Karger AG, Basel</rights><rights>Copyright © 2015 by S. Karger AG, Basel 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</citedby><cites>FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478321/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4478321/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26195972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yılmaz, Mustafa</creatorcontrib><creatorcontrib>Aydınalp, Alp</creatorcontrib><creatorcontrib>Okyay, Kaan</creatorcontrib><creatorcontrib>Tekin, Abdullah</creatorcontrib><creatorcontrib>Bal, Uğur Abbas</creatorcontrib><creatorcontrib>Bayraktar, Nilüfer</creatorcontrib><creatorcontrib>Yıldırır, Aylin</creatorcontrib><creatorcontrib>Müderrisoğlu, Haldun</creatorcontrib><title>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</title><title>Cardiorenal medicine</title><addtitle>Cardiorenal Med</addtitle><description>Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p &lt; 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.</description><subject>Original Paper</subject><issn>1664-3828</issn><issn>1664-5502</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptkc1r3DAQxUVoSUKaQ-4hCHJpD24lWZLlSyCYfgSStpT2LGRZ9jr1Ss7IXtj_vjK73bSlp5lhfrx5w0PogpK3lIryHSEkV7SU_AidUil5JgRhL_Z9rpg6QecxPiaMCElLIo7RCUuNKAt2inwV1qOBPgaPQ4srAxvX9EMYsPENfnBTGCEsYxsAfwW3cX7qfYer4CcwccrufDNb1-DPblxBGM202mLTTg4SAsEb2OJb3_WhAzOutq_Qy9YM0Z3v6xn68eH99-pTdv_l4111e59ZLtiUMSOplTVnnElmbUmlZVJK09bGGpvXXFlSt8vXTpiCKm6buuCqILlUwhKZn6Gbne4412vXWLe4HfQI_To50sH0-u-N71e6CxvNeaFyRpPA670AhKfZxUmv-2jdMBjvwhw1laUiea54kdDrf9DHMINP7y2UKEpZKJGoNzvKQogRXHswQ4legtSHIBN79af7A_k7tueTPw10Dg5A9e1hJ6HHpk3U5X-p_ZVfPFSu3A</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Yılmaz, Mustafa</creator><creator>Aydınalp, Alp</creator><creator>Okyay, Kaan</creator><creator>Tekin, Abdullah</creator><creator>Bal, Uğur Abbas</creator><creator>Bayraktar, Nilüfer</creator><creator>Yıldırır, Aylin</creator><creator>Müderrisoğlu, Haldun</creator><general>S. Karger AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201506</creationdate><title>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</title><author>Yılmaz, Mustafa ; Aydınalp, Alp ; Okyay, Kaan ; Tekin, Abdullah ; Bal, Uğur Abbas ; Bayraktar, Nilüfer ; Yıldırır, Aylin ; Müderrisoğlu, Haldun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yılmaz, Mustafa</creatorcontrib><creatorcontrib>Aydınalp, Alp</creatorcontrib><creatorcontrib>Okyay, Kaan</creatorcontrib><creatorcontrib>Tekin, Abdullah</creatorcontrib><creatorcontrib>Bal, Uğur Abbas</creatorcontrib><creatorcontrib>Bayraktar, Nilüfer</creatorcontrib><creatorcontrib>Yıldırır, Aylin</creatorcontrib><creatorcontrib>Müderrisoğlu, Haldun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiorenal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yılmaz, Mustafa</au><au>Aydınalp, Alp</au><au>Okyay, Kaan</au><au>Tekin, Abdullah</au><au>Bal, Uğur Abbas</au><au>Bayraktar, Nilüfer</au><au>Yıldırır, Aylin</au><au>Müderrisoğlu, Haldun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography</atitle><jtitle>Cardiorenal medicine</jtitle><addtitle>Cardiorenal Med</addtitle><date>2015-06</date><risdate>2015</risdate><volume>5</volume><issue>3</issue><spage>199</spage><epage>207</epage><pages>199-207</pages><issn>1664-3828</issn><eissn>1664-5502</eissn><abstract>Aims: Contrast-induced nephropathy (CIN) is one of the most common causes of hospital-acquired acute renal failure. Oxidative stress and vasoconstriction might play key roles in its pathogenesis. In a few experimental models, antioxidant properties of carvedilol have been documented. The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of CIN in patients undergoing coronary angiography. Methods: One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study. Venous blood samples were obtained before and 48 h after contrast administration. Cystatin C and malondialdehyde values were examined and compared. CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value. Results: Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003). In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration. In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94). In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p &lt; 0.001). In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59). Conclusion: When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26195972</pmid><doi>10.1159/000381964</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3828
ispartof Cardiorenal medicine, 2015-06, Vol.5 (3), p.199-207
issn 1664-3828
1664-5502
language eng
recordid cdi_crossref_primary_10_1159_000381964
source Open Access: PubMed Central
subjects Original Paper
title Comparison of Carvedilol and Metoprolol for Preventing Contrast-Induced Nephropathy after Coronary Angiography
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A50%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Carvedilol%20and%20Metoprolol%20for%20Preventing%20Contrast-Induced%20Nephropathy%20after%20Coronary%20Angiography&rft.jtitle=Cardiorenal%20medicine&rft.au=Y%C4%B1lmaz,%20Mustafa&rft.date=2015-06&rft.volume=5&rft.issue=3&rft.spage=199&rft.epage=207&rft.pages=199-207&rft.issn=1664-3828&rft.eissn=1664-5502&rft_id=info:doi/10.1159/000381964&rft_dat=%3Cproquest_cross%3E3741611051%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-2a61c6b424262cc916c2666afbacac3b48c0bf8196e5a7184cdb748703685c063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1695796785&rft_id=info:pmid/26195972&rfr_iscdi=true